TOTAL AND FREE PLASMA AND TOTAL SYNOVIAL-FLUID PIROXICAM CONCENTRATIONS - RELATIONSHIP TO ANTIINFLAMMATORY EFFECT IN PATIENTS WITH REACTIVE ARTHRITIS AND OTHER ARTHRITIDES

被引:9
作者
HUNDAL, O
KVIEN, TK
GLENNAS, A
ANDRUP, O
KARSTENSEN, B
THOEN, JE
RUGSTAD, HE
机构
[1] NATL HOSP NORWAY,DEPT CLIN PHARMACOL,OSLO 1,NORWAY
[2] UNIV OSLO,DEPT PHARM,PHARMACEUT CHEM SECT,OSLO 3,NORWAY
[3] NORWEGIAN LUTHERAN HOSP,OSLO CITY DEPT RHEUMATOL,OSLO,NORWAY
关键词
REACTIVE ARTHRITIS; PIROXICAM; TOTAL PLASMA CONCENTRATION; FREE PLASMA CONCENTRATION; SYNOVIAL FLUID CONCENTRATION;
D O I
10.3109/03009749309099268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Twentyfive patients (14 males, 11 females), sixteen with reactive arthritis and 9 with other arthritides were treated with piroxicam, 40 mg at day 1 and 20 mg daily the following 9 days. Both local knee joint and general disease activity were assessed at day 0 and day 10. At day 10, plasma and synovial fluid were drawn. Total and free (determined after equilibrium dialysis) plasma concentrations and total synovial fluid concentrations were measured by HPLC. Total plasma piroxicam concentrations (mug/ml) were 4.1 (0.5-8.3) [median (range)], free piroxicam plasma concentrations were 0.051 (0.012-0.118), total synovial fluid concentrations were 2.2 (0.34.6) and ratios total synovial to total plasma concentration were 0.51 (0.39-0.90). The effect of piroxicam treatment varied among the patients. We found no relationship between drug concentration and change in any of the disease activity parameters nor any correlation between the ratio of synovial fluid to plasma piroxicam concentration and the local knee joint disease activity parameters.
引用
收藏
页码:183 / 187
页数:5
相关论文
共 15 条
[1]   RELATIONSHIP OF SERUM NAPROXEN CONCENTRATION TO EFFICACY IN RHEUMATOID-ARTHRITIS [J].
DAY, RO ;
FURST, DE ;
DROMGOOLE, SH ;
KAMM, B ;
ROE, R ;
PAULUS, HE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (06) :733-740
[2]  
GLENNAS A, 1991, HUNG RHEUMATOL S, P79
[3]   DOSE-RESPONSE STUDY WITH IBUPROFEN IN RHEUMATOID-ARTHRITIS - CLINICAL AND PHARMACOKINETIC FINDINGS [J].
GRENNAN, DM ;
AARONS, L ;
SIDDIQUI, M ;
RICHARDS, M ;
THOMPSON, R ;
HIGHAM, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (03) :311-316
[4]  
GRENNAN DM, 1985, NONSTEROIDAL ANTIINF, P151
[5]  
HUNDAL O, 1991, FUNDAM CLIN PHARM, V5, P275
[6]   NAPROXEN FREE PLASMA-CONCENTRATIONS AND UNBOUND FRACTIONS IN PATIENTS WITH OSTEOARTHRITIS - RELATION TO AGE, SEX, EFFICACY, AND ADVERSE EVENTS [J].
HUNDAL, O ;
RUGSTAD, HE ;
HUSBY, G .
THERAPEUTIC DRUG MONITORING, 1991, 13 (06) :478-484
[7]  
HUNDALO, IN PRESS CLIN RHEUMA
[8]   TRANSSYNOVIAL KINETICS OF PIROXICAM IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].
KUROWSKI, M ;
DUNKY, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (04) :401-406
[9]  
KVIEN TK, 1982, J RHEUMATOL, V9, P696
[10]  
LIGNIERE GC, 1987, ARZNEIMITTEL-FORSCH, V37, P460